InMed Pharmaceuticals (INM) EBIT Growth (1y) (2022 - 2026)
InMed Pharmaceuticals (INM) EBIT Growth (1y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.41 Bn | 39.75 Bn | 2.15 Bn | -150.77% |
| 3 | Zoetis | 31.83 Bn | 30.15 Bn | 1.05 Bn | -10.00% |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.97 Bn | 5.10 Bn | -0.93% |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | -9.25% |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | -97.30% |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 4.05% |
| 8 | Elanco Animal Health | 11.93 Bn | 11.40 Bn | 798.00 Mn | 12.73% |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | - |
| 10 | InMed Pharmaceuticals | 6.56 Mn | 1.32 Mn | - | -46.32% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -23.64% |
| Dec 31, 2025 | 6.72% |
| Sep 30, 2025 | -4.94% |
| Jun 30, 2025 | -21.33% |
| Mar 31, 2025 | -3.45% |
| Dec 31, 2024 | -37.03% |
| Sep 30, 2024 | 35.09% |
| Jun 30, 2024 | -319.30% |
| Mar 31, 2024 | 14.29% |
| Dec 31, 2023 | 25.70% |
| Sep 30, 2023 | 25.26% |
| Jun 30, 2023 | 92.56% |
| Mar 31, 2023 | 39.20% |
| Dec 31, 2022 | 48.66% |
| Sep 30, 2022 | -20.34% |